净利润飙升50%!CRO龙头Q4业绩公布

生物药大时代
12 Feb

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。近日,海外CRO龙头Medpace公布2024年业绩:截至 2024 年 12 月 31 日止,全年收入21.09亿美元,同比增长11.8% 。其中Q4营收5.366 亿美元,同比增长7.7%,积压订单转化率为 18.3%。值得注意的是,Q4净利润激增...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10